1. Home
  2. ALLO vs TMQ Comparison

ALLO vs TMQ Comparison

Compare ALLO & TMQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • TMQ
  • Stock Information
  • Founded
  • ALLO 2017
  • TMQ 2004
  • Country
  • ALLO United States
  • TMQ Canada
  • Employees
  • ALLO N/A
  • TMQ N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • TMQ Precious Metals
  • Sector
  • ALLO Health Care
  • TMQ Basic Materials
  • Exchange
  • ALLO Nasdaq
  • TMQ Nasdaq
  • Market Cap
  • ALLO 252.9M
  • TMQ 249.6M
  • IPO Year
  • ALLO 2018
  • TMQ N/A
  • Fundamental
  • Price
  • ALLO $1.27
  • TMQ $4.27
  • Analyst Decision
  • ALLO Buy
  • TMQ
  • Analyst Count
  • ALLO 11
  • TMQ 0
  • Target Price
  • ALLO $8.67
  • TMQ N/A
  • AVG Volume (30 Days)
  • ALLO 2.3M
  • TMQ 6.9M
  • Earning Date
  • ALLO 11-06-2025
  • TMQ 09-30-2025
  • Dividend Yield
  • ALLO N/A
  • TMQ N/A
  • EPS Growth
  • ALLO N/A
  • TMQ N/A
  • EPS
  • ALLO N/A
  • TMQ N/A
  • Revenue
  • ALLO N/A
  • TMQ N/A
  • Revenue This Year
  • ALLO N/A
  • TMQ N/A
  • Revenue Next Year
  • ALLO $100.00
  • TMQ N/A
  • P/E Ratio
  • ALLO N/A
  • TMQ N/A
  • Revenue Growth
  • ALLO N/A
  • TMQ N/A
  • 52 Week Low
  • ALLO $0.86
  • TMQ $0.99
  • 52 Week High
  • ALLO $3.78
  • TMQ $11.29
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 53.43
  • TMQ 49.61
  • Support Level
  • ALLO $1.16
  • TMQ $3.40
  • Resistance Level
  • ALLO $1.28
  • TMQ $4.16
  • Average True Range (ATR)
  • ALLO 0.09
  • TMQ 0.35
  • MACD
  • ALLO 0.01
  • TMQ -0.06
  • Stochastic Oscillator
  • ALLO 70.68
  • TMQ 62.95

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

Share on Social Networks: